Undisclosed BsADC therapeutic / Biocytogen, ABL Bio - LARVOL DELTA

Biocytogen Enters Collaboration with ABL Bio to Develop New Bispecific Antibody-Drug Conjugates (Businesswire) - "Biocytogen Pharmaceuticals...today announced a collaboration to develop new bispecific antibody-drug conjugates (bsADCs)....This collaboration is one of the stepping stones for getting down to developing bsADCs. We look forward to a productive collaboration, and firmly believe that this partnership will contribute towards creating a distinctive pipeline, ultimately leading to novel therapies that improve the quality of life for patients.'"

Licensing / partnership • Oncology